Lenvima capsules 4 mg for unresectable thyroid carcinoma (lenvatinib mesylate, lenvatinib mesilate)
What are Lenvima capsules (lenvatinib sylate, lenvatinib melate) 4 mg for unresectable thyroid cancer?
An active principle of Lenvima capsules is lenvatinib, an anti-tumor agent developed by Japanese pharmaceutical company Eisai. It inhibits kinases involved in cancerogenic signaling pathways, and, by this, inhibits proliferation and vascularization of tumor cells. Lenvatinib is absorbed quickly, its plasma concentrations reaches the peak in 1-4 hours (3-7 if taken with meals). Also, this medicine has a high bioavailability profile (around 85%).
Lenvima capsules are effective for the treatment of severely unresectable thyroid cancer. Studies showed that lenvatinib significantly increases progression-free survival (18.3 months in a lenvatinib treatment group, 3.6 months in a placebo treatment group) and the response rate (64% in the lenvatinib treatment group, 1.5% in placebo group). However, adverse effects such as blood pressure changes are possible.
Active principles: lenvatinib mesylate
Amount: 20 capsules
Maker: Eisai Co., Ltd., Tokyo, Japan
Indications: unresectable thyroid cancer
How to take
Adults should take 24 mg of active principle (6 capsules) once a day. Your doctor may reduce or increase the dosage according to your symptoms.
This medication contains 4 mg of active principle in 1 capsule.
Contraindications: do not use for pregnant, possibly pregnant, or breastfeeding women.
Patient should receive full blood test at least once a month.
As this medicine may cause dizziness, patient should be careful when operating dangerous machinery, driving a vehicle, or working at heights.
If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.